Inactive Instrument

Analyst Reco. Cytosorbents Corp OTC Bulletin Board

Equities

HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50	Dec. 29	MT
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating	Dec. 28	MT
US STOCKS -Wall Street edges higher as year end approaches, rate cuts in focus	Dec. 28	RE
B. Riley Resumes Cytosorbents at Buy With $4 PT; Notes CytoSorb's Growth Potential, Risk-Adjusted Revenue Contribution of DrugSorb-ATR in US	23-09-07	MT
HC Wainwright Adjusts Price Target on Cytosorbents to $5.50 From $9, Maintains Buy Rating	22-11-04	MT
B. Riley Trims Cytosorbents' Price Target to $6 from $7, Lowers Revenue Estimates Despite Confidence for Mid-Term; Keeps Buy Rating	22-05-04	MT
HC Wainwright Adjusts Cytosorbents' Price Target to $9 from $13, Keeps Buy Rating	22-05-04	MT
B. Riley Lowers Cytosorbents' Price Target to $7 from $10, Notes Continued H1 Headwinds, Lowers Revenue Estimate for 2022; Keeps Buy Rating	22-03-10	MT
CYTOSORBENTS : B. Riley Resumes Cytosorbents at Buy with $10 PT, Says Headwinds Represent Buying Opportunity	21-10-14	MT
CYTOSORBENTS : B. Riley Adjusts Cytosorbents' Price Target to $17 From $16, Keeps Buy Rating	21-01-04	MT

No results for this search